OLIG2 and neuroblastoma: In neuroblastoma Neuro-2a cells treated with ETO, a widely used antitumor agent [33], the number of BrdU+ cells was significantly higher in cells that overexpressed WT Olig2 than those transfected with the 3KR mutant (Fig. 2a), which argues for an essential role of SUMOylation in the protective effect of Olig2 against cell cycle arrest.